Clinical Trials Sponsored by Italfarmaco

Total 35 results

Italfarmaco

Completed

A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD

Duchenne Muscular Dystrophy (DMD)

Italy
Italfarmaco

Completed

Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity

Drug-Drug Interaction

Portugal
Italfarmaco

Terminated

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Italy
Italfarmaco

Terminated

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Hodgkin's Lymphoma

Italy
Italfarmaco

Completed

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy

Becker Muscular Dystrophy

Netherlands, Italy
Italfarmaco

Completed

ITF2984 Repeated Doses Study in Healthy Volunteers (MAD)

Healthy Male Volunteers

Italy, United Kingdom
Italfarmaco

Active, not recruiting

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Chronic Myeloproliferative Neoplasms

Germany, Italy, United Kingdom
Italfarmaco

Completed

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

Duchenne and Becker Muscular Dystrophy | Polycytemia Vera

Canada
Italfarmaco

Completed

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Myeloproliferative Diseases

Italy
Italfarmaco

Completed

Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV)

Polycythemia Vera

Italy
Italfarmaco

Completed

A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers (14 days MAD)

Healthy

Italy
Italfarmaco

Completed

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Metastatic Cancer | Advanced Cancer

Italy
Italfarmaco

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera (GIV-IN PV)

Polycythemia Vera

United States
Italfarmaco

Recruiting

A Multicentre, Prospective, Open-label, Non-comparative Study

Contraception

Italy
Italfarmaco

Recruiting

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)

Duchenne Muscular Dystrophy

Canada, Italy, France, Belgium, Germany, Netherlands, United Kingdom
Italfarmaco

Completed

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

Drug Drug Interaction

Portugal
Italfarmaco

Terminated

Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease (CD)

Crohn's Disease

Belgium, Italy, Netherlands
Italfarmaco

Completed

Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

Drug Drug Interaction

Portugal
Italfarmaco

Terminated

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Italy
Italfarmaco

Completed

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

Italy
Italfarmaco

Completed

Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis (SOJIA)

Active Systemic | Onset Juvenile Idiopathic Arthritis

Romania, Serbia
Italfarmaco

Completed

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Polycythemia Vera

Germany, Poland, United Kingdom, Italy, France
Italfarmaco

Completed

Phase II Study With ITF2984 in Acromegalic Patients (POC)

Acromegaly

France, Hungary, Netherlands, Serbia, Czech Republic, Italy, Spain, Poland, Romania
Italfarmaco

Terminated

Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis

Polyarticular Course Juvenile Idiopathic Arthritis

Belgium, Spain, Serbia, Czech Republic, Italy, Romania, Slovenia
Italfarmaco S.A

Completed

Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.

Vaginal Atrophy

Spain
Italfarmaco
Cromsource

Enrolling by invitation

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Duchenne Muscular Dystrophy

Spain, United States, Canada, Belgium, France, Israel, Italy, Netherlands, Serbia, Germany, United Kingdom
Italfarmaco
Parexel

Terminated

Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

Czechia
Italfarmaco
Syneos Health

Completed

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Italy, Spain, Canada, Belgium, France, Germany, Israel, Netherlands, Serbia, United Kingdom
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Open Non-Comparative Study To Evaluate Administration Of a New Nutraceutical

Sleep Disorder

Romania
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®

Vaginal Disease

Romania
Italfarmaco
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Prevalence And Burden Of Nausea And Vomiting In Pregnant Women (PURITY)

Nausea Gravidarum | Vomiting of Pregnancy

Italy
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara

Vaginal Disease

Romania
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®

Vaginal Disease

Romania
Institut Investigacio Sanitaria Pere Virgili
Italfarmaco; Instituto de Salud Carlos III; European Regional Development Fund; Universitat Rovira i Virgili and other collaborators

Completed

The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.

Intrauterine Development

Spain
Jett Foundation, Inc.
Pfizer; Hoffmann-La Roche; Italfarmaco; Nationwide Children's Hospital; Capricor... and other collaborators

Completed

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Duchenne Muscular Dystrophy | Rare Diseases | Disability Physical | Burden, Dependency | Impairment | Disease Management

United States

3

Subscribe